Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis

References

• HelmickCGFelsonDTLawrenceRCEstimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part IArthritis Rheum200858152518163481
   PubMed Web of Science ®Google Scholar
• ArthritisFRheumatoid arthritis fact sheet2009http://www.arthritis.org/media/newsroom/media-kits/Rheumatoid_Arthritis_Fact_Sheet.pdf
   Google Scholar
• OlivieriIPalazziCPeruzGPadulaAManagement issues with elderly-onset rheumatoid arthritis: an updateDrugs Aging20052280982216245956
   PubMed Web of Science ®Google Scholar
• JacksonCGWilliamsHJDisease-modifying antirheumatic drugs. Using their clinical pharmacological effects as a guide to their selectionDrugs1998563373449777310
   PubMed Web of Science ®Google Scholar
• NurmohamedMTDijkmansBAEfficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritisDrugs20056566169415748099
   PubMed Web of Science ®Google Scholar
• ChoyEHPanayiGSCytokine pathways and joint inflammation in rheumatoid arthritisN Engl J Med200134490791611259725
   PubMed Web of Science ®Google Scholar
• Van SnickJInterleukin-6: an overviewAnnu Rev Immunol199082532782188664
   PubMed Web of Science ®Google Scholar
• GenoveseMCKaineJLLowensteinMBOcrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging studyArthritis Rheum2008582652266118759293
   PubMed Web of Science ®Google Scholar
• HiranoTMatsudaTTurnerMExcessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritisEur J Immunol198818179718012462501
   PubMed Web of Science ®Google Scholar
• AgencyEMRoActemra (Tocilizumab: summary of product characteristics): summary of product characteristics2009
   Google Scholar
• A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology responseArthritis Rheum20075719320217330293
   PubMedGoogle Scholar
• McInnesIBSchettGCytokines in the pathogenesis of rheumatoid arthritisNat Rev Immunol2007742944217525752
   PubMed Web of Science ®Google Scholar
• NielenMMvan SchaardenburgDReesinkHWSimultaneous development of acute phase response and autoantibodies in preclinical rheumatoid arthritisAnn Rheum Dis20066553553716079166
   PubMed Web of Science ®Google Scholar
• NiewoldTBHarrisonMJPagetSAAnti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritisQJM200710019320117434910
   PubMed Web of Science ®Google Scholar
• LallyFSmithEFilerAA novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synoviumArthritis Rheum2005523460346916255036
   PubMed Web of Science ®Google Scholar
• RomanoMSironiMToniattiCRole of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitmentImmunity199763153259075932
   PubMed Web of Science ®Google Scholar
• KaplanskiGMarinVMontero-JulianFMantovaniAFarnarierCIL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammationTrends Immunol200324252912495721
   PubMed Web of Science ®Google Scholar
• MiharaMKasutaniKOkazakiMTocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine familyInt Immunopharmacol200551731174016102523
   PubMed Web of Science ®Google Scholar
• SackUKinneRWMarxTHepptPBenderSEmmrichFInterleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritisRheumaltology Int1993134551
   PubMed Web of Science ®Google Scholar
• StreetzKLTackeFLeifeldLInterleukin 6/gp130-dependent pathways are protective during chronic liver diseasesHepatology20033821822912830005
   PubMed Web of Science ®Google Scholar
• CastellJVGomez-LechonMJDavidMInterleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytesFEBS Lett19892422372392464504
   PubMed Web of Science ®Google Scholar
• GauldieJSauderDNMcAdamKPDinarelloCAPurified interleukin-1 (IL-1) from human monocytes stimulates acute-phase protein synthesis by rodent hepatocytes in vitroImmunology1987602032072434417
   PubMed Web of Science ®Google Scholar
• RidkerPMCookNClinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk ScoresCirculation20041091955195915051634
   PubMed Web of Science ®Google Scholar
• RidkerPMRifaiNStampferMJHennekensCHPlasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy menCirculation20001011767177210769275
   PubMed Web of Science ®Google Scholar
• BiasucciLMLiuzzoGFantuzziGIncreasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary eventsCirculation1999992079208410217645
   PubMed Web of Science ®Google Scholar
• NishimotoNKishimotoTHumanized antihuman IL-6 receptor antibody, tocilizumabHandb Exp Pharmacol200815116018071945
   PubMedGoogle Scholar
• HibiMMurakamiMSaitoMHiranoTTagaTKishimotoTMolecular cloning and expression of an IL-6 signal transducer, gp130Cell199063114911572261637
   PubMed Web of Science ®Google Scholar
• ChoyEHIsenbergDAGarroodTTherapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trialArthritis Rheum2002463143315012483717
   PubMed Web of Science ®Google Scholar
• MainiRNTaylorPCSzechinskiJDouble-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexateArthritis Rheum2006542817282916947782
   PubMed Web of Science ®Google Scholar
• FleishmanRTocilizumab inhibits radiographic progression and improves physical function in rheumatoid arthritis patients at 2 years with increasing clinical efficacy over timeProceedings ACRPhiladelphia, PA10182009
   Google Scholar
• NishimotoNHashimotoJMiyasakaNStudy of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader-blinded randomised controlled trial of tocilizumabAnn Rheum Dis2007661162116717485422
   PubMed Web of Science ®Google Scholar
• NishimotoNMiyasakaNYamamotoKStudy of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapyMod Rheumatol200919121918979150
   PubMed Web of Science ®Google Scholar
• SmolenJSBeaulieuARubbert-RothAEffect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialLancet200837198799718358926
   PubMed Web of Science ®Google Scholar
• EmeryPKeystoneETonyHPIL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trialAnn Rheum Dis2008671516152318625622
   PubMed Web of Science ®Google Scholar
• GenoveseMCMcKayJDNasonovELInterleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid-arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy studyArthritis Rheum2008582968298018821691
   PubMed Web of Science ®Google Scholar
• JonesGSebbaAGuJComparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION studyAnn Rheum Dis201069889619297346
   PubMed Web of Science ®Google Scholar
• NishimotoNYoshizakiKMiyasakaNTreatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trialArthritis Rheum2004501761176915188351
   PubMed Web of Science ®Google Scholar
• EmeryPFleischmannRFilipowicz-SosnowskaAThe efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trialArthritis Rheum2006541390140016649186
   PubMed Web of Science ®Google Scholar
• SmolenJSHanCvan der HeijdeDMRadiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockadeAnn Rheum Dis20096882382718593759
   PubMed Web of Science ®Google Scholar
• KandaJKawabataHYamajiYReversible cardiomyopathy associated with Multicentric Castleman disease: successful treatment with tocilizumab, an anti-interleukin 6 receptor antibodyInt J Hematol20078520721117483056
   PubMed Web of Science ®Google Scholar
• HoffmeisterARothenbacherDKunzeMBrennerHKoenigWPrognostic value of inflammatory markers alone and in combination with blood lipids in patients with stable coronary artery diseaseEur J Intern Med200516475215733822
   PubMedGoogle Scholar
• LarssonPTHallerstamSRosforsSWallenNHCirculating markers of inflammation are related to carotid artery atherosclerosisInt Angiol200524435115876998
   PubMed Web of Science ®Google Scholar
• HedmanALarssonThomasPDo preoperative inflammatory parameters predict early graft occlusion and late cardiovascular eventsCat Ins2007
   Google Scholar
• ConwayDSBugginsPHughesELipGYPrognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillationAm Heart J200414846246615389233
   PubMed Web of Science ®Google Scholar
• BhattDLFoxKAHackeWClopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic eventsN Engl J Med20063541706171716531616
   PubMed Web of Science ®Google Scholar